Anatara Lifesciences Ltd (AU:ANR) has released an update.
Anatara Lifesciences reports successful progress in the second stage of its GaRP-IBS trial, with recruitment reaching 43 participants and strong interest across multiple Australian sites. The trial, aimed at addressing the unmet need for IBS treatment, has also secured a European patent for its GaRP product, extending protection until 2039. Anatara anticipates completing recruitment by Q4 2024 and expects headline results in early 2025.
For further insights into AU:ANR stock, check out TipRanks’ Stock Analysis page.